<DOC>
	<DOCNO>NCT00763438</DOCNO>
	<brief_summary>The purpose study permit patient schizophrenia receive Sertindole previous randomise trial , study 99824 , continue treatment .</brief_summary>
	<brief_title>Safety Study Antipsychotic , Sertindole , Treat Schizophrenia</brief_title>
	<detailed_description>Schizophrenia disable often chronic disorder may require long-term treatment . This protocol extension study randomise study compare safety Sertindole versus Risperidone . Patients randomise Sertindole complete previous study possibility receive continue Sertindole treatment open one-arm study . Sertindole generally well tolerate approve EU , yet market France . The follow-up patient similar previous study require quarterly visit . Patient management reflect routine clinical practice accordance Sertindole label . Any severe safety issue report company .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Sertindole</mesh_term>
	<criteria>Participation previous SCoP study , 99824 Still fulfils EU SPC requirement Sertindole Withdrawn end SCoP study , 99824 Become homeless Participation another clinical trial time Unlikely comply clinical study protocol unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Sertindole</keyword>
	<keyword>Safety study</keyword>
</DOC>